{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T20:32:28Z","timestamp":1747168348542,"version":"3.40.5"},"reference-count":37,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","nucmedbio.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.nucmedbio.2015.12.004","type":"journal-article","created":{"date-parts":[[2016,1,6]],"date-time":"2016-01-06T12:46:43Z","timestamp":1452084403000},"page":"227-231","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Safety and efficacy of radioimmunotherapy (RIT) in treatment of non-Hodgkin's lymphoma in the community setting"],"prefix":"10.1016","volume":"43","author":[{"given":"Tarik","family":"Hadid","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Raufi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zyad","family":"Kafri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Mandziara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Kalabat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Szpunar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3179-7855","authenticated-orcid":false,"given":"Kleanthe","family":"Kolizeras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Steigelman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5684-948X","authenticated-orcid":false,"given":"Ayad","family":"Al-Katib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2015","series-title":"Non-Hodkin's Lymphoma","author":"American Cancer Society","key":"10.1016\/j.nucmedbio.2015.12.004_bb0005"},{"year":"2015","series-title":"Leading Sites of New Cancer Cases and Deaths \u2014 2015 Estimates","author":"American Cancer Society","key":"10.1016\/j.nucmedbio.2015.12.004_bb0010"},{"key":"10.1016\/j.nucmedbio.2015.12.004_bb0015","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1517\/14712598.2013.786698","article-title":"Rituximab in the treatment of non-Hodgkin's lymphoma-a critical evaluation of randomized controlled trials","volume":"13","author":"Griffin","year":"2013","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.nucmedbio.2015.12.004_bb0020","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/jnci\/djk152","article-title":"Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis","volume":"99","author":"Schulz","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.nucmedbio.2015.12.004_bb0025","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3121\/cmr.3.3.157","article-title":"Radioimmunotherapy for non-Hodgkin's lymphoma","volume":"3","author":"Rao","year":"2005","journal-title":"Clin Med Res"},{"key":"10.1016\/j.nucmedbio.2015.12.004_bb0030","doi-asserted-by":"crossref","first-page":"830","DOI":"10.2967\/jnumed.110.085589","article-title":"Radioimmunotherapy in non-Hodgkin lymphoma: opinions of nuclear medicine physicians and radiation oncologists","volume":"52","author":"Schaefer","year":"2011","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2015.12.004_bb0035","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.3109\/10428194.2011.570396","article-title":"Treatment recommendations for radioimmunotherapy in follicular lymphoma: a consensus conference report","volume":"52","author":"Witzig","year":"2011","journal-title":"Leuk Lymphoma"},{"year":"2012","series-title":"Bexxar Package Insert","author":"GlaxoSmithKline","key":"10.1016\/j.nucmedbio.2015.12.004_bb0040"},{"year":"2013","series-title":"Zevalin Package Insert","author":"Spectrum Pharmaceuticals Inc.","key":"10.1016\/j.nucmedbio.2015.12.004_bb0045"},{"key":"10.1016\/j.nucmedbio.2015.12.004_bb0050","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"year":"2009","series-title":"Common Terminology Criteria for Adverse Events version 4.03","author":"National Cancer Institute","key":"10.1016\/j.nucmedbio.2015.12.004_bb0055"},{"key":"10.1016\/j.nucmedbio.2015.12.004_bb0060","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1634\/theoncologist.5-5-376","article-title":"Monoclonal antibody therapy in lymphoid malignancies","volume":"5","author":"Hainsworth","year":"2000","journal-title":"Oncologist"},{"key":"10.1016\/j.nucmedbio.2015.12.004_bb0065","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","article-title":"Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.nucmedbio.2015.12.004_bb0070","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1097\/00006231-200309000-00002","article-title":"The radiation biology of radioimmunotherapy","volume":"24","author":"Dixon","year":"2003","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.nucmedbio.2015.12.004_bb0075","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2001.19.19.3918","article-title":"Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas","volume":"19","author":"Kaminski","year":"2001","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.nucmedbio.2015.12.004_bb0080","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2010-02-269753","article-title":"Radioimmunotherapy of relapsed indolent non-Hodgkin lymphoma with 131I-rituximab in routine clinical practice: 10-year single-institution experience of 142 consecutive patients","volume":"117","author":"Leahy","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.nucmedbio.2015.12.004_bb0085","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1089\/cbr.2004.19.478","article-title":"Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia","volume":"19","author":"Schilder","year":"2004","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.nucmedbio.2015.12.004_bb0090","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1200\/JCO.2002.11.017","article-title":"Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.nucmedbio.2015.12.004_bb0095","doi-asserted-by":"crossref","first-page":"7565","DOI":"10.1200\/JCO.2004.00.9217","article-title":"Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas","volume":"23","author":"Fisher","year":"2005","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.nucmedbio.2015.12.004_bb0100","doi-asserted-by":"crossref","first-page":"5156","DOI":"10.1200\/JCO.2008.17.2015","article-title":"Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma","volume":"26","author":"Morschhauser","year":"2008","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.nucmedbio.2015.12.004_bb0105","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1200\/JCO.2009.27.8325","article-title":"Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter phase II study","volume":"28","author":"Link","year":"2010","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.nucmedbio.2015.12.004_bb0110","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.clml.2012.09.012","article-title":"A systematic literature review and meta-analysis of radioimmunotherapy consolidation for patients with untreated follicular lymphoma","volume":"12","author":"Rose","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.nucmedbio.2015.12.004_bb0115","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1200\/JCO.2007.13.5376","article-title":"Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma","volume":"26","author":"Marcus","year":"2008","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.nucmedbio.2015.12.004_bb0120","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1182\/blood-2007-01-068056","article-title":"Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation","volume":"110","author":"Morschhauser","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.nucmedbio.2015.12.004_bb0125","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1182\/blood-2003-11-3883","article-title":"Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1\/2 study","volume":"103","author":"Gordon","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.nucmedbio.2015.12.004_bb0130","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1002\/cncr.22617","article-title":"Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan","volume":"109","author":"Witzig","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.nucmedbio.2015.12.004_bb0135","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive Non-Hodgkin's lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nucmedbio.2015.12.004_bb0140","first-page":"748","article-title":"Final results of a phase II study of sequential R-CHOP and Yttrium-90 ibritumomab tiuxetan (RIT) for elderly high risk patients with untreated diffuse large B-cell lymphoma (DLBCL)","author":"Hamlin","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.nucmedbio.2015.12.004_bb0145","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.1158\/1078-0432.CCR-10-0162","article-title":"Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients","volume":"16","author":"Zinzani","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nucmedbio.2015.12.004_bb0150","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1743-7563.2011.01393.x","article-title":"Radioimmunotherapy with (131)I-rituximab for patients with relapsed\/refractory B-cell non-Hodgkin's lymphoma (NHL)","volume":"7","author":"Kang","year":"2011","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1016\/j.nucmedbio.2015.12.004_bb0155","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.freeradbiomed.2007.10.048","article-title":"Regulation of CD20 expression by radiation-induced changes in intracellular redox status","volume":"44","author":"Gupta","year":"2008","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.nucmedbio.2015.12.004_bb0160","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.ijrobp.2010.09.044","article-title":"Outcomes of patients with non-Hodgkin's lymphoma treated with Bexxar with or without external-beam radiotherapy","volume":"82","author":"Smith","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.nucmedbio.2015.12.004_bb0165","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/cncr.21998","article-title":"Safety and efficacy of external beam radiation therapy for non-Hodgkin lymphoma in patients with prior 90Y-ibritumomab tiuxetan radioimmunotherapy","volume":"107","author":"Justice","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.nucmedbio.2015.12.004_bb0170","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1056\/NEJMoa041511","article-title":"131I-tositumomab therapy as initial treatment for follicular lymphoma","volume":"352","author":"Kaminski","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nucmedbio.2015.12.004_bb0175","doi-asserted-by":"crossref","first-page":"4576","DOI":"10.1182\/blood-2004-12-4690","article-title":"Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab","volume":"105","author":"Bennett","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.nucmedbio.2015.12.004_bb0180","doi-asserted-by":"crossref","first-page":"4935","DOI":"10.1200\/JCO.2010.29.1112","article-title":"Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype","volume":"28","author":"Morton","year":"2010","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.nucmedbio.2015.12.004_bb0185","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1200\/JCO.2009.26.8748","article-title":"Radioimmunotherapy of lymphoma: a treatment approach ahead of its time or past its sell-by date?","volume":"28","author":"Illidge","year":"2010","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805115300743?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805115300743?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,16]],"date-time":"2018-09-16T06:00:04Z","timestamp":1537077604000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969805115300743"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S0969805115300743"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2015.12.004","relation":{},"ISSN":["0969-8051"],"issn-type":[{"type":"print","value":"0969-8051"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of radioimmunotherapy (RIT) in treatment of non-Hodgkin's lymphoma in the community setting","name":"articletitle","label":"Article Title"},{"value":"Nuclear Medicine and Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2015.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}